查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951776

生物标记发现外包服务市场分析及预测（至2035年）：依类型、产品类型、服务、技术、组件、应用、最终用户、流程、模式

Biomarker Discovery Outsourcing Services Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Process, Mode
出版日期: | 出版商: Global Insight Services | 英文 305 Pages | 商品交期: 3-5个工作天内

价格
简介目录

生物标记发现外包服务市场预计将从2024年的152亿美元成长到2034年的414亿美元，复合年增长率约为11.4%。该市场涵盖第三方提供的用于识别、检验和开发诊断、预后和治疗应用生物标记的服务。推动该市场成长的因素包括：对个人化医疗日益增长的需求、体学技术的进步以及对经济高效解决方案的需求。外包服务使製药和生技公司能够获得专业知识和最尖端科技，从而加速药物研发并提高临床试验效率。

在个人化医疗和先进诊断技术需求不断增长的推动下，生物标记发现外包服务市场持续发展。服务板块在该市场中呈现最高成长率，这主要得益于生物标记检验服务在临床试验和药物研发中的重要角色。生物标记鑑定服务是成长第二快的板块，这主要得益于治疗领域对新型生物标记的持续探索。在技​​术领域，基因组学是领先的子板块，主要得益于基因组技术在生物标记发现中日益广泛的应用。蛋白质体学是成长第二快的子板块，反映出其在理解疾病机制的重要性日益凸显。在应用领域，鑑于癌症的高发生率和对标靶治疗的需求，肿瘤学正成为重点领域。神经学正成为成长第二快的板块，主要得益于神经退化性疾病研究的进展。策略伙伴关係和技术创新对于增强服务能力和推动市场成长至关重要。

市场区隔
按类型 基因生物标誌物、蛋白质体生物标记、代谢体学生物标记、转录组生物标记物
产品 检测试剂盒、试剂、设备及软体
服务 生物标记检验、生物标记检测、生物标记鑑定、生物标记开发
科技 质谱分析、PCR、次世代定序（NGS）、免疫检测
成分 硬体、软体和服务
应用领域 诊断、药物研发、个人化医疗、临床试验
最终用户 製药公司、生技公司、研究机构、合约研究组织
过程 临床前、临床及上市后
实施例 内部开发，外包

生物标誌物发现外包服务市场呈现出多元化的市场份额分布，主要参与者不断推出创新产品以掌握新的机会。技术进步和竞争压力正在影响定价策略，促使企业在提供附加价值服务的同时优化成本结构。策略联盟和伙伴关係关係日益增多，增强了服务能力并拓展了全球业务。这种动态环境为能够快速回应不断变化的客户需求和监管要求的企业提供了竞争优势。竞争标竿分析显示，主要企业之间竞争激烈，他们透过差异化和创新力争获得优势。监管的影响至关重要，严格的合规标准塑造了营运结构和服务交付模式。北美和欧洲监管机构制定的严格准则对市场产生影响，进而影响服务交付。能够有效应对监管环境的企业将能更好地利用合规优势，最大限度地掌握成长机会。在对个人化和精准医疗解决方案日益增长的需求驱动下，该市场蕴藏着巨大的成长潜力。

主要趋势和驱动因素：

受个人化医疗和生物技术进步的推动，生物标誌物发现外包服务市场正经历强劲成长。主要趋势包括製药公司与学术机构之间合作的加强，这提高了研究能力并加速了生物标记的发现。精准医疗的兴起也进一步推动了市场需求，因为生物标记对于开发标靶治疗和改善患者预后至关重要。高通量筛检和次世代定序等技术创新正在革新生物标记发现流程。这些创新能够有效率地识别潜在的生物标记物，从而缩短药物研发的时间并降低成本。此外，人工智慧 (AI) 和机器学习在数据分析中的应用提高了生物标记识别的准确性和预测能力。医疗基础设施和研发投入的增加也是市场的主要驱动因素。新兴市场由于成本效益和专业知识的获取，生物标誌物发现服务的外包需求正在成长。提供全面灵活服务模式的公司能够更能掌握这些机会。市场对疾病早期检测和医疗保健的关注也为其持续成长提供了支撑。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 基因生物标誌物
    • 蛋白质体学生物标誌物
    • 代谢体学物标誌物
    • 转录组学生物标誌物
  • 市场规模及预测：依产品划分
    • 检测试剂盒
    • 试剂
    • 装置
    • 软体
  • 市场规模及预测：依服务划分
    • 生物标记检验
    • 生物标记检测
    • 生物标记鑑定
    • 生物标誌物开发
  • 市场规模及预测：依技术划分
    • 质谱分析
    • PCR
    • 次世代定序（NGS）
    • 免疫检测
  • 市场规模及预测：依组件划分
    • 硬体
    • 软体
    • 服务
  • 市场规模及预测：依应用领域划分
    • 诊断
    • 药物发现
    • 个人化医疗
    • 临床试验
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 研究所
    • CRO（合约研究组织）
  • 市场规模及预测：依製程划分
    • 临床前阶段
    • 临床
    • 售后
  • 市场规模及预测：按模式
    • 内部开发
    • 外包

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Charles River Laboratories
  • ICON plc
  • Syneos Health
  • Medpace
  • Parexel International
  • Covance
  • Bio Agilytix Labs
  • IQVIA
  • Eurofins Scientific
  • PPD
  • Wu Xi App Tec
  • Frontage Laboratories
  • Evotec
  • Genocea Biosciences
  • Proteome Sciences
  • Quanterix
  • Bioclinica
  • Bioserve
  • Selvita
  • Biodesix

第九章：关于我们

简介目录
Product Code: GIS26272

Biomarker Discovery Outsourcing Services Market is anticipated to expand from $15.2 billion in 2024 to $41.4 billion by 2034, growing at a CAGR of approximately 11.4%. The Biomarker Discovery Outsourcing Services Market encompasses services provided by third-party organizations to identify, validate, and develop biomarkers for diagnostic, prognostic, and therapeutic applications. This market is driven by the growing demand for personalized medicine, advancements in omics technologies, and the need for cost-effective solutions. Outsourcing enables pharmaceutical and biotech companies to leverage specialized expertise and state-of-the-art technologies, thereby accelerating drug development and enhancing clinical trial efficiency.

The Biomarker Discovery Outsourcing Services Market is evolving, fueled by the rising need for personalized medicine and advanced diagnostics. Within this market, the services segment is the top performer, led by biomarker validation services due to their critical role in clinical trials and drug development. Biomarker identification services follow, driven by the ongoing search for novel biomarkers in therapeutic areas. The technology segment sees genomics as a leading sub-segment, propelled by the increasing application of genomic technologies in biomarker discovery. Proteomics ranks as the second highest performing sub-segment, reflecting its growing importance in understanding disease mechanisms. The application segment highlights oncology as the foremost area, given the high prevalence of cancer and the demand for targeted therapies. Neurology emerges as the second highest performing segment, supported by advancements in neurodegenerative disorder research. Strategic partnerships and technological innovations are pivotal, enhancing service offerings and driving market growth.

Market Segmentation
TypeGenomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Transcriptomic Biomarkers
ProductAssay Kits, Reagents, Instruments, Software
ServicesBiomarker Validation, Biomarker Testing, Biomarker Identification, Biomarker Development
TechnologyMass Spectrometry, PCR, NGS, Immunoassays
ComponentHardware, Software, Services
ApplicationDiagnostics, Drug Discovery, Personalized Medicine, Clinical Trials
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, CROs
ProcessPreclinical, Clinical, Post-market
ModeIn-house, Outsourced

The Biomarker Discovery Outsourcing Services Market is characterized by a diverse landscape of market share distribution, with key players launching innovative products to capture emerging opportunities. Pricing strategies are influenced by technological advancements and competitive pressures, driving companies to optimize cost structures while delivering value-added services. The market is witnessing a surge in strategic alliances and partnerships, enhancing service offerings and expanding global reach. This dynamic environment fosters a competitive edge for firms that can swiftly adapt to evolving client demands and regulatory requirements. Competition benchmarking reveals a robust rivalry among leading service providers, each vying for dominance through differentiation and technological innovation. Regulatory influences play a pivotal role, with stringent compliance standards shaping operational frameworks and service delivery models. The market is influenced by regulatory bodies in North America and Europe, which set stringent guidelines that impact service offerings. Companies that effectively navigate these regulatory landscapes are poised to capitalize on growth opportunities, leveraging compliance as a strategic advantage. The market is ripe with potential, driven by the increasing demand for personalized medicine and precision healthcare solutions.

Geographical Overview:

The biomarker discovery outsourcing services market is witnessing notable growth across various regions, each presenting unique opportunities. North America dominates the market, attributed to advanced healthcare infrastructure and increased research activities. The presence of leading biotechnology firms further bolsters the region's market position. Europe follows, driven by government support for research and stringent regulatory frameworks that enhance biomarker validation. Asia Pacific emerges as a promising growth pocket. The region benefits from rising healthcare investments and an increasing focus on precision medicine. Countries like China and India are at the forefront, spurred by expanding biopharmaceutical sectors. Latin America and the Middle East & Africa are burgeoning markets with untapped potential. Latin America is experiencing increased clinical research activities, while the Middle East & Africa are recognizing the growing importance of biomarkers in personalized medicine. These regions are progressively investing in infrastructure to support biomarker discovery, thus offering lucrative opportunities for market expansion.

The Biomarker Discovery Outsourcing Services Market is being significantly influenced by global tariff policies, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, the focus is shifting towards bolstering domestic capabilities to mitigate dependencies on foreign biotechnological imports, especially under the strain of US-China trade tensions. China's strategic initiatives are pivoting towards enhancing local biopharma innovation, while Taiwan leverages its expertise in precision medicine amidst geopolitical uncertainties. The parent market of biopharmaceuticals is witnessing robust growth, driven by advances in personalized medicine and increased R&D investments. By 2035, the market is expected to flourish through strategic regional collaborations and technological advancements. Middle Eastern conflicts are exerting pressure on energy prices, indirectly affecting operational costs and supply chain stability in the biomarker sector.

Key Trends and Drivers:

The Biomarker Discovery Outsourcing Services Market is experiencing robust growth driven by advancements in personalized medicine and biotechnology. A key trend is the increasing collaboration between pharmaceutical companies and academic institutions, which enhances research capabilities and accelerates biomarker discovery. The rise of precision medicine is further propelling demand, as biomarkers are crucial for developing targeted therapies and improving patient outcomes. Technological advancements, such as high-throughput screening and next-generation sequencing, are revolutionizing biomarker discovery processes. These innovations enable more efficient identification of potential biomarkers, reducing time and costs associated with drug development. Additionally, the integration of artificial intelligence and machine learning in data analysis is enhancing the accuracy and predictive power of biomarker identification. Growing investments in healthcare infrastructure and research and development are significant market drivers. Emerging markets are witnessing increased outsourcing of biomarker discovery services due to cost-effectiveness and access to specialized expertise. Companies that offer comprehensive and flexible service models are well-positioned to capitalize on these opportunities. The focus on early disease detection and preventive healthcare underscores the market's potential for sustained growth.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Genomic Biomarkers
    • 4.1.2 Proteomic Biomarkers
    • 4.1.3 Metabolomic Biomarkers
    • 4.1.4 Transcriptomic Biomarkers
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Assay Kits
    • 4.2.2 Reagents
    • 4.2.3 Instruments
    • 4.2.4 Software
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Biomarker Validation
    • 4.3.2 Biomarker Testing
    • 4.3.3 Biomarker Identification
    • 4.3.4 Biomarker Development
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Mass Spectrometry
    • 4.4.2 PCR
    • 4.4.3 NGS
    • 4.4.4 Immunoassays
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Hardware
    • 4.5.2 Software
    • 4.5.3 Services
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Diagnostics
    • 4.6.2 Drug Discovery
    • 4.6.3 Personalized Medicine
    • 4.6.4 Clinical Trials
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Biotechnology Companies
    • 4.7.3 Research Institutes
    • 4.7.4 CROs
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Clinical
    • 4.8.3 Post-market
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 In-house
    • 4.9.2 Outsourced

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Process
      • 5.2.1.9 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Process
      • 5.2.2.9 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Process
      • 5.2.3.9 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Process
      • 5.3.1.9 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Process
      • 5.3.2.9 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Process
      • 5.3.3.9 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Process
      • 5.4.1.9 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Process
      • 5.4.2.9 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Process
      • 5.4.3.9 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Process
      • 5.4.4.9 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Process
      • 5.4.5.9 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Process
      • 5.4.6.9 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Process
      • 5.4.7.9 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Process
      • 5.5.1.9 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Process
      • 5.5.2.9 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Process
      • 5.5.3.9 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Process
      • 5.5.4.9 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Process
      • 5.5.5.9 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Process
      • 5.5.6.9 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Process
      • 5.6.1.9 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Process
      • 5.6.2.9 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Process
      • 5.6.3.9 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Process
      • 5.6.4.9 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Process
      • 5.6.5.9 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Charles River Laboratories
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 ICON plc
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Syneos Health
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Medpace
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Parexel International
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Covance
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Bio Agilytix Labs
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 IQVIA
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Eurofins Scientific
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 PPD
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Wu Xi App Tec
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Frontage Laboratories
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Evotec
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Genocea Biosciences
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Proteome Sciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Quanterix
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Bioclinica
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Bioserve
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Selvita
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Biodesix
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us